Small-molecule inhibitors of vascular adhesion protein-1 reduce the accumulation of myeloid cells into tumors and attenuate tumor growth in mice

Journal of Immunology

Volumn 184, Issue 6, 2010, Pages 3164-3173

  Marttila Ichihara, Fumiko ^a,c   Castermans, Karolien ^d   Auvinen, Kaisa ^a,c   Oude Egbrink, Mirjam G A ^e,f   Jalkanen, Sirpa ^a,c   Griffioen, Arjan W ^d   Salmi, Marko ^a,b,c  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1 METHYLHYDRAZINO) 1 INDANOL; 3 FLUORO 2 (4 METHOXYBENZYL)ALLYLAMINE HYDROCHLORIDE; CD11B ANTIGEN; LJP 1586; MONOCLONAL ANTIBODY; PROTEIN INHIBITOR; SZE 5302; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1; VASCULAR ADHESION PROTEIN 1 MONOCLONAL ANTIBODY; 3 FLUORO 2 (4 METHOXYBENZYL)ALLYLAMINE; 3-FLUORO-2-(4-METHOXYBENZYL)ALLYLAMINE; ALLYLAMINE; AMINE OXIDASE (COPPER CONTAINING); BLOCKING ANTIBODY; CARBAMOHYDRAZIDE; CELL ADHESION MOLECULE; DRUG DERIVATIVE; ENZYME INHIBITOR; GROWTH INHIBITOR; IMMUNOLOGICAL ADJUVANT; SEMICARBAZIDE DERIVATIVE; SEMICARBAZIDE SENSITIVE AMINE OXIDASE VASCULAR ADHESION PROTEIN 1, MOUSE; SEMICARBAZIDE-SENSITIVE AMINE OXIDASE-VASCULAR ADHESION PROTEIN-1, MOUSE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MACROPHAGE; MELANOMA; MICROSCOPY; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL MELANOMA; IMMUNOLOGY; MIGRATION INHIBITION; PATHOLOGY; T CELL LYMPHOMA; TUMOR CELL LINE; VASCULARIZATION;

ADJUVANTS, IMMUNOLOGIC; ALLYLAMINE; AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MIGRATION INHIBITION; ENZYME INHIBITORS; FEMALE; GROWTH INHIBITORS; LYMPHOMA, T-CELL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MYELOID CELLS; SEMICARBAZIDES;

EID: 77951909461     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901794     Document Type: Article

References (44)

1. Mantovani, A., P. Allavena, A. Sica, and F. Balkwill. 2008. Cancer-related inflammation. Nature 454: 436-444.
2. Ley, K., C. Laudanna, M. I. Cybulsky, and S. Nourshargh. 2007. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7: 678-689.
3. Balkwill, F. 2004. Cancer and the chemokine network. Nat. Rev. Cancer 4: 540-550.
4. Salmi, M., and S. Jalkanen. 2001. VAP-1: an adhesin and an enzyme. Trends Immunol. 22: 211-216.
5. Salmi, M., K. Kalimo, and S. Jalkanen. 1993. Induction and function of vascular adhesion protein-1 at sites of inflammation. J. Exp. Med. 178: 2255-2260.
6. Salmi, M., and S. Jalkanen. 1992. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 257: 1407-1409.
7. Jaakkola, K., T. Nikula, R. Holopainen, T. Vähäsilta, M.-T. Matikainen, M.-L. Laukkanen, R. Huupponen, L. Halkola, L. Nieminen, J. Hiltunen, et al. 2000. In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am. J. Pathol. 157: 463-471.
8. Bonder, C. S., M. U. Norman, M. G. Swain, L. D. Zbytnuik, J. Yamanouchi, P. Santamaria, M. Ajuebor, M. Salmi, S. Jalkanen, and P. Kubes. 2005. Rules of recruitment of trafficking Th1 and Th2 cells in inflamed liver: a role for alpha-4 integrin and vascular adhesion protein-1. Immunity 23: 153-163.
9. Salmi, M., G. G. Yegutkin, R. Lehvonen, K. Koskinen, T. Salminen, and S. Jalkanen. 2001. Acell surface amine oxidase directly controls lymphocytemigration. Immunity 14: 265-276.
10. Salmi, M., and S. Jalkanen. 1996. Human vascular adhesion protein 1 (VAP-1) is a unique sialoglycoprotein that mediates carbohydrate-dependent binding of lymphocytes to endothelial cells. J. Exp. Med. 183: 569-579.
11. Salmi, M., S. Tohka, E. L. Berg, E. C. Butcher, and S. Jalkanen. 1997. Vascular adhesion protein 1 (VAP-1) mediates lymphocyte subtype-specific, selectin-independent recognition of vascular endothelium in human lymph nodes. J. Exp. Med. 186: 589-600.
12. Tohka, S., M.-L. Laukkanen, S. Jalkanen, and M. Salmi. 2001. Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates recruitment in vivo. FASEB J. 15: 373-382. (Pubitemid 32141429)
13. Lalor, P. F., S. Edwards, G. McNab, M. Salmi, S. Jalkanen, and D. H. Adams. 2002. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J. Immunol. 169: 983-992.
14. Martelius, T., V. Salaspuro, M. Salmi, L. Krogerus, K. Höckerstedt, S. Jalkanen, and I. Lautenschlager. 2004. Blockade of vascular adhesion protein-1 inhibits lymphocyte infiltration in rat liver allograft rejection. Am. J. Pathol. 165: 1993-2001.
15. Koskinen, K., P. J. Vainio, D. J. Smith, M. Pihlavisto, S. Ylä-Herttuala, S. Jalkanen, and M. Salmi. 2004. Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 103: 3388-3395. (Pubitemid 38525669)
16. Xu, H.-L., L. Salter-Cid, M. D. Linnik, E. Y. Wang, C. Paisansathan, and D. A. Pelligrino. 2006. Vascular adhesion protein-1 plays an important role in postischemic inflammation and neuropathology in diabetic, estrogen-treated ovariectomized female rats subjected to transient forebrain ischemia. J. Pharmacol. Exp. Ther. 317: 19-29.
17. O'Rourke, A. M., E. Y. Wang, A. Miller, E. M. Podar, K. Scheyhing, L. Huang, C. Kessler, H. Gao, H. T. Ton-Nu, M. T. Macdonald, et al. 2008. Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity. J. Pharmacol. Exp. Ther. 324: 867-875.
18. Salter-Cid, L. M., E. Wang, A. M. O'Rourke, A. Miller, H. Gao, L. Huang, A. Garcia, and M. D. Linnik. 2005. Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase. J. Pharmacol. Exp. Ther. 315: 553-562.
19. Marttila-Ichihara, F., D. J. Smith, C. Stolen, G. G. Yegutkin, K. Elima, N. Mercier, R. Kiviranta, M. Pihlavisto, S. Alaranta, U. Pentikäinen, et al. 2006. Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. Arthritis Rheum. 54: 2852-2862.
20. Noda, K., S. Miyahara, T. Nakazawa, L. Almulki, S. Nakao, T. Hisatomi, H. She, K. L. Thomas, R. C. Garland, J. W. Miller, et al. 2008. Inhibition of vascular adhesion protein-1 suppresses endotoxin-induced uveitis. FASEB J. 22: 1094-1103.
21. Salmi, M., and S. Jalkanen. 2005. Cell-surface enzymes in control of leukocyte trafficking. Nat. Rev. Immunol. 5: 760-771.
22. + myeloid cells into tumors. Cancer Res. 69: 7875-7883.
23. Vainio, P. J., O. Kortekangas-Savolainen, J. H. Mikkola, K. Jaakkola, K. Kalimo, S. Jalkanen, and T. Veromaa. 2005. Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis. Basic Clin. Pharmacol. Toxicol. 96: 429-435.
24. O'Rourke, A. M., E. Y. Wang, L. Salter-Cid, L. Huang, A. Miller, E. Podar, H. F. Gao, D. S. Jones, and M. D. Linnik. 2007. Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis. J. Neural Transm. 114: 845-849.
25. Fischer, C., B. Jonckx, M. Mazzone, S. Zacchigna, S. Loges, L. Pattarini, E. Chorianopoulos, L. Liesenborghs, M. Koch, M. De Mol, et al. 2007. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475.
26. Merinen, M., H. Irjala, M. Salmi, I. Jaakkola, A. Hänninen, and S. Jalkanen. 2005. Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am. J. Pathol. 166: 793-800.
27. Dirkx, A. E., M. G. Oude Egbrink, M. J. Kuijpers, S. T. van der Niet, V. V. Heijnen, J. C. Bouma-ter Steege, J. Wagstaff, and A. W. Griffioen. 2003. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 63: 2322-2329.
28. Dirkx, A. E., M. G. oude Egbrink, K. Castermans, D. W. van der Schaft, V. L. Thijssen, R. P. Dings, L. Kwee, K. H. Mayo, J. Wagstaff, J. C. Bouma-ter Steege, and A. W. Griffioen. 2006. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20: 621-630.
29. Salmi, M., P. Rajala, and S. Jalkanen. 1997. Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte-subtype specific adhesion. J. Clin. Invest. 99: 2165-2172.
30. Stolen, C. M., F. Marttila-Ichihara, K. Koskinen, G. G. Yegutkin, R. Turja, P. Bono, M. Skurnik, A. Hänninen, S. Jalkanen, and M. Salmi. 2005. Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity 22: 105-115.
31. Stamper, H. B., Jr., and J. J. Woodruff. 1976. Lymphocyte homing into lymph nodes: in vitro demonstration of the selective affinity of recirculating lymphocytes for high-endothelial venules. J. Exp. Med. 144: 828-833.
32. Kobayashi, H., K. C. Boelte, and P. C. Lin. 2007. Endothelial cell adhesion molecules and cancer progression. Curr. Med. Chem. 14: 377-386.
33. Kiss, J., S. Jalkanen, F. Fülöp, T. Savunen, and M. Salmi. 2008. Ischemia-reperfusion injury is attenuated in VAP-1-deficient mice and by VAP-1 inhibitors. Eur. J. Immunol. 38: 3041-3049.
34. Gabrilovich, D. I., V. Bronte, S. H. Chen, M. P. Colombo, A. Ochoa, S. Ostrand-Rosenberg, and H. Schreiber. 2007. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67: 425-, author reply 426.
35. Cheng, P., C. A. Corzo, N. Luetteke, B. Yu, S. Nagaraj, M. M. Bui, M. Ortiz, W. Nacken, C. Sorg, T. Vogl, et al. 2008. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205: 2235-2249.
36. Lalor, P. F., P. J. Sun, C. J. Weston, A. Martin-Santos, M. J. Wakelam, and D. H. Adams. 2007. Activation of vascular adhesion protein-1 on liver endothelium results in an NF-κB-dependent increase in lymphocyte adhesion. Hepatology 45: 465-474.
37. Jalkanen, S., M. Karikoski, N. Mercier, K. Koskinen, T. Henttinen, K. Elima, K. Salmivirta, and M. Salmi. 2007. The oxidase activity of vascular adhesion protein-1 (VAP-1) induces endothelial E- and P-selectins and leukocyte binding. Blood 110: 1864-1870. (Pubitemid 47443898)
38. Xia, C., Q. Meng, L. Z. Liu, Y. Rojanasakul, X. R. Wang, and B. H. Jiang. 2007. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res. 67: 10823-10830. (Pubitemid 350145911)
39. Solé, M., M. Hernandez-Guillamon, M. Boada, and M. Unzeta. 2008. p53 phosphorylation is involved in vascular cell death induced by the catalytic activity of membrane-bound SSAO/VAP-1. Biochim. Biophys. Acta 1783: 1085-1094.
40. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
41. Yoong, K. F., G. McNab, S. G. Hübscher, and D. H. Adams. 1998. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J. Immunol. 160: 3978-3988.
42. Irjala, H., M. Salmi, K. Alanen, R. Grénman, and S. Jalkanen. 2001. Vascular adhesion protein 1 mediates binding of immunotherapeutic effector cells to tumor endothelium. J. Immunol. 166: 6937-6943. (Pubitemid 32467241)
43. Varis, A., M. Wolf, O. Monni, M. L. Vakkari, A. Kokkola, C. Moskaluk, H. Frierson, Jr., S. M. Powell, S. Knuutila, A. Kallioniemi, and W. El-Rifai. 2002. Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res. 62: 2625-2629. (Pubitemid 34462744)
44. Airenne, T. T., Y. Nymalm, H. Kidron, D. J. Smith, M. Pihlavisto, M. Salmi, S. Jalkanen, M. S. Johnson, and T. A. Salminen. 2005. Crystal structure of the human vascular adhesion protein-1: unique structural features with functional implications. Protein Sci. 14: 1964-1974.